News
Start-up introduces ‘AI-powered’ mental health assessments for corporate wellness platforms
The capabilities are hoped to help corporate wellness programme administrators to better track employee wellness over time
The US mental health start-up Aiberry has announced a new version of its platform designed to meet the needs of corporate wellness platform users.
The platform uses an “AI-powered” therapeutic assistant to conduct a conversation to detect mental health disorders by analysing what is being said, the speech patterns being used and subtle changes in facial expressions.
New analytics capabilities introduced as part of the Aiberry corporate wellness platform are hoped to help corporate wellness programme administrators to track utilisation of the platform as well as employee wellness over time.
The company’s initiative comes at a time when the need for mental health programmes in the workplace has never been greater.
A recent survey conducted by Lyra Health revealed that while 86 per cent of employees say they have experienced at least one mental health challenge in the last year, only 33 per cent have received care.
An additional 33 per cent of employees said that their benefits fail to address their mental health needs, while 48 per cent of managers say they lack the resources and training needed to support team members’ mental health.
Research shows women are twice as likely as men to experience anxiety disorders such as panic attacks. They are also more likely to experience depression than men, with one in four women developing depression at some point in life.
The availability of virtual, AI-powered platforms could help bridge the gap between what is needed and what is currently available by providing access to better initial assessments and continuous mental health monitoring.
Linda Chung, Aiberry co-founder and co-CEO, said: “The expansion of the Aiberry platform into corporate wellness brings the benefits of AI-powered mental health assessment to a critical population, American workers, which is massively underserved by currently-available behavioural health resources.
“This delivers on our mission to offer objective, reliable, and scalable solutions via the power of AI, making behavioural healthcare accessible to all, and helps bring our vision, to empower patients and providers with the tools to effectively and efficiently assess behavioural health, to reality.”
Thomas M. Tegler, president at the corporate wellness management and technology company Wellworks For You, said: “The ability for us to introduce Aiberry into our clients’ corporate wellness programmes is great for us, but even better for them.
“Aiberry not only allows them to offer assessments whenever and wherever they need them, at any scale, but the new analytics embedded in the platform allows us to give them very specific guidance about where the areas of concern are within their employee population and what additional programs and resources they may need to address them.
“The result is that we become a better partner to them, and, most importantly, the health and wellness of their employees improve.”
Aiberry said the expansion of its platform for corporate wellness builds on a solid foundation of use in clinical settings including leading national recovery centres.
These facilities have seen assessment accuracy and patient wellbeing improve measurably since the platform was implemented, the company added.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now







1 Comment